Company intelligence / Profile preview
Neuraly
Baltimore, Maryland, USAneuralymed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 2 trial of NLY01 in Parkinson's disease with topline results announced in March 2023. Also received FDA clearance for Phase 2B trial of NLY01 in Alzheimer's disease patients.
- Therapeutic areas
- Neurology
- Modalities
- GLP-1R agonistssmall moleculesc-Abl inhibitors
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Enigma Biomedical USA1st Biotherapeutics Inc.
Beyond the preview
Go deeper on Neuraly.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuraly.